Immunomedics (IMMU) was founded in 1982. Thirty-seven years later, the biotech is finally on the cusp of its first marketing approval — possibly ending one of the longest drug-development droughts in the industry’s history.
On Friday, the Food and Drug Administration is expected to render an approval decision on sacituzumab govitecan, an antibody drug conjugate developed by Immunomedics to treat women with triple-negative breast cancer. As its name implies, these breast cancer cells do not carry receptors for estrogen, progesterone, or human epidermal growth factor, which are targeted by such drugs as Herceptin or tamoxifen.
Well written, great summary
Comments are closed.